149 related articles for article (PubMed ID: 2182236)
1. The APSAC interventional mortality study (AIMS) trial: mortality data.
Julian DG
Clin Cardiol; 1990 Mar; Suppl 5():V20-1; discussion V27-32. PubMed ID: 2182236
[TBL] [Abstract][Full Text] [Related]
2. Increased survival after APSAC: 30-day and 12-month mortality data from the APSAC Intervention Mortality Study.
Julian DG
Am J Cardiol; 1989 Jul; 64(2):27A-29A; discussion 41A-42A. PubMed ID: 2662740
[TBL] [Abstract][Full Text] [Related]
3. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
[No Abstract] [Full Text] [Related]
4. Anisoylated plasminogen streptokinase activator complex versus placebo. A preliminary multicentre study of safety and early mortality in acute myocardial infarction.
Julian DG; Borthwick LS; Reid D; Jennings KP; Wainwright RJ; Rodger JC; Wood D; Phillips WS
Drugs; 1987; 33 Suppl 3():261-7. PubMed ID: 3315604
[TBL] [Abstract][Full Text] [Related]
5. Long-term effects of intravenous anistreplase in acute myocardial infarction: final report of the AIMS study. AIMS Trial Study Group.
Lancet; 1990 Feb; 335(8687):427-31. PubMed ID: 1968167
[TBL] [Abstract][Full Text] [Related]
6. The safety of anistreplase from the placebo-controlled AIMS study (anistreplase Intervention Mortality Study). The AIMS Study Group.
Fox KA
Clin Cardiol; 1990 Mar; Suppl 5():V22-6; discussion V27-32. PubMed ID: 2182237
[TBL] [Abstract][Full Text] [Related]
7. An interim report of the efficacy and safety of anisoylated plasminogen streptokinase activator complex (APSAC).
Johnson ES; Cregeen RJ
Drugs; 1987; 33 Suppl 3():298-311. PubMed ID: 3315612
[TBL] [Abstract][Full Text] [Related]
8. An interim report of a double-blind placebo-controlled recanalisation study of anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
Timmis AD; Griffin B; Crick JC; Flax JS; Sowton E
Drugs; 1987; 33 Suppl 3():146-50. PubMed ID: 3315582
[TBL] [Abstract][Full Text] [Related]
9. Multicenter reperfusion trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: controlled comparison with intracoronary streptokinase.
Anderson JL; Rothbard RL; Hackworthy RA; Sorensen SG; Fitzpatrick PG; Dahl CF; Hagan AD; Browne KF; Symkoviak GP; Menlove RL
J Am Coll Cardiol; 1988 Jun; 11(6):1153-63. PubMed ID: 3284943
[TBL] [Abstract][Full Text] [Related]
10. Tolerance and complications in a multicenter trial of intravenous APSAC and intracoronary streptokinase in acute myocardial infarction.
Rothbard RL; Anderson JL; Fitzpatrick PG; Hakworthy RA; Sorensen SG; Marder VJ
Clin Cardiol; 1990 Mar; Suppl 5():V11-4; discussion V27-32. PubMed ID: 2182234
[TBL] [Abstract][Full Text] [Related]
11. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
Cassagnes J; Bassand JP; Machecourt J; Lusson JR; Anguenot T; Borel E; Vacher D; Denis B; Maurat JP; Jallut H
Arch Mal Coeur Vaiss; 1990 Apr; 83(4):453-60. PubMed ID: 2111665
[TBL] [Abstract][Full Text] [Related]
12. Reperfusion in acute myocardial infarction. A multicentre randomised trial of early intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in the United States.
Anderson JL
Drugs; 1987; 33 Suppl 3():154-62. PubMed ID: 3315584
[TBL] [Abstract][Full Text] [Related]
13. Comparison of intravenous anisoylated plasminogen streptokinase activator complex with intracoronary streptokinase in acute myocardial infarction.
Bonnier JJ
Drugs; 1987; 33 Suppl 3():151-3. PubMed ID: 3315583
[TBL] [Abstract][Full Text] [Related]
14. Acylated plasminogen-streptokinase activator complex: a new approach to thrombolytic therapy.
Crabbe SJ; Grimm AM; Hopkins LE
Pharmacotherapy; 1990; 10(2):115-26. PubMed ID: 2140889
[TBL] [Abstract][Full Text] [Related]
15. Comparison of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
Bonnier HJ; Visser RF; Klomps HC; Hoffmann HJ
Am J Cardiol; 1988 Jul; 62(1):25-30. PubMed ID: 3289357
[TBL] [Abstract][Full Text] [Related]
16. ISIS-3: a randomised comparison of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group.
Lancet; 1992 Mar; 339(8796):753-70. PubMed ID: 1347801
[TBL] [Abstract][Full Text] [Related]
17. [Fibrinolysis therapy using APSAC in acute myocardial infarct].
Hochrein H
Dtsch Med Wochenschr; 1990 Jun; 115(25):999. PubMed ID: 2193790
[No Abstract] [Full Text] [Related]
18. The effect of thrombolytic therapy with anisoylated plasminogen streptokinase activator complex on the indicators of myocardial salvage.
Buchalter MB; Bourke JP; Jennings K; Adams PC; Kenmure AC; Hah CW; Reid DS
Drugs; 1987; 33 Suppl 3():209-15. PubMed ID: 3315593
[TBL] [Abstract][Full Text] [Related]
19. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
Croydon EA
Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611
[TBL] [Abstract][Full Text] [Related]
20. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
Monassier JP; Hanssen M
Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
